Table 1

Studies reporting at least one VKA quality control measure

StudyDisease stateStudy designVKA-treated NVKA studiedTarget INRTTR, %PINRR, %Mean/median INRMean/median doseMonitoring frequencyINR variabilityINR testing interval, days*PPIROther*
Abdelhafiz and Wheeldon20AFPD402W2–3••••
Abdelhafiz and Wheeldon21AFPD402W2–3••••
Agnelli et al 22DVTRCT134W,A2–3•
Agnelli et al 23PERCT165W,A2–3•
Agnelli et al 24DVTRCT126W,A,P2–3•
Agnelli et al 7VTERCT27042–3•
Albers et al 25AFRCT1962W2–3•••
Amiwero et al 26VTERCT126W2–3•••
Anderson27AFRD87W2–3••
Ansell et al 18AFRD1511W, A, F2–3••••••
Aujesky et al 28PERCT339W,A,P,F2–3•
Bona et al 29VTEPD98W2–3•
Boulanger et al 30AFRD6431W2–3••••
Büller et al 31PERCT2184–2–3•
Büller et al 32DVTRCT137W,A,P,F2–3••
Büller et al 33PERCT1595W2–3•
Burton et al 34AFRD259W2–3•••
Cafolla et al 35AF/VTEPD871W,A, other2–3•
Cafolla et al 36AFPD112W2–3/
1.5–2.5		•••
Campbell et al 37VTERCT749W2–3.5•
Cheung et al 38AFRD555W1.5–3•
Chitsike et al 39VTEPD349W2–3••
Chung et al 40AFRCT75W2–3•
Coleman et al 41AFPD65W2–3••
Connolly et al 42AFRCT3371–2–3•
Connolly et al 43AFRCT3371–2–3•
Connollyet al 6AFRCT6022W2–3•
Copland et al 44AFRD328W1.8–3.3••
Currie et al 45AFRD1513W2–3••••••
Daskalopoulos et al 46DVTRCT52A2–3•
Dimberg et al 47AFRD791W2–3••
Douketis et al 48VTERCT1021–2–3•
Easton et al 49AFRCT1643W2–3•
The Einstein Investigators49aDVTRCT1718W,A2–3•
The Einstein Investigators49bPERCT2413W,A2–3•
Ellis et al 50AFRCT66T2–3••••
Evans et al 51AFPD288W2–3••
Evans et al 52AFPD214W2–3••
Ezekowitz et al 53AFRCT70W2–3•
Ezekowitz et al 54AFRCT6022W2–3•
Fiessinger et al 55VTERCT1249W2–3•
Ford et al 56AFRCT3665W2–3••
Gadisseur et al 57DVTPD266A,P2.5–3.5••
Gallagher et al 58AFRD18 113W2–3••
Gallagher et al 59VTERD10 381W,A,P2–3••
Garcia et al 60AFRCT9081W2–3•
Go et al 61AFRD6320W2–3••
Gomberg-Maitland et al 62AFRCT3624W2–3•
Granger et al 8AFRCT9081W2–3•
Hankey et al 63AFRCT7133W2–3•
Heidinger et al 64AF/DVTPD1375–2–3•
Ho et al 65AFRD476W2–3•••
Hokusai-VTE Investigators65aVTERCT4122W2–3•
Holmes et al 66AFRCT244W2–3•
Hori et al 67AFRCT108W2–3/
2–2.6		•
Hori et al 68AFRCT639W2–3/
1.6–2.6		•
Hutten et al 69VTERCT1039–2–3•
Hylek et al 70AFPD472W2–3••
Hylek et al 71AFRCT3665W2–3••
Jacobs et al 72AFRD90W2–3••
Jones et al 73AFRD2223W2–3•••••
Kalra et al 74AFPD167W2–3••
Kearon et al 75VTERCT738W2–3/
1.5–1.9		•••
Kearon et al 76VTERCT81W2–3••
Kearon et al 77VTERCT703W2–3•
Kim et al 78AFRD129W2–3•••••
Kim et al 79AF/VTEPD646W2–3•
Kulo et al 80AFPD/RD117W,A2–3•••••
Kulo et al 81AFPD/RD117W,A2–3•••••
Kurtoglu et al 82DVTPD246W2–3••
Lee et al 83AFPD/RD200W2–3•••
Lip et al 84AFRCT318–2–3•
Lopez-Beret et al 85DVTRCT77A2–3•
Malik and Taylor 86AF/VTERD328W2–3•
Mant et al 87AFRCT488W2–3••
Matchar et al 88AFRCT363W2–3••
Matchar 89AFRCT363W2–3••
McBride et al 90AFPD324W2–3•
McCormick et al 91AFRD174W2–3••
Melamed et al 92AFRD906W2–3•••
Menzin et al 93AFRD600W2–3••
Morgan et al 94AFRD2235W2–3••
Naganuma et al 95AFRD845W1.5–2.5•
Nakatani et al 96AFR95W2–3/
1.6–2.6		••••
Neree et al 97AFRD395W,P,A2–3••••
Nichol et al 98AFRD1107W2–3••
Nieuwlaat et al 99AFRCT266–2–3•••
Njaastad et al 100AF/VTERD936W2–3•
Nozawa et al 101AFPD156W1.6–1.9••••
Obata et al 102AFRD110W1.6–2.6••••••
Ogawa et al 103AFRCT74W2–3/
2–2.6		•
Okumura et al 104AFPD501W2–3/
1.6–2.6		•••
Olsson 105AFRCT1703W2–3••
Olsson et al 106AFRCT83W2–3•
Ombandza-Moussa et al 107VTERD81––•
Ono and Fujita108AFPD63W1.5–2.5•••
Palareti et al 109VTEPD733W, A2–3••
Palareti et al 110VTEPD297W, A2–3•
Patel et al 1AFRCT7133W2–3•
Pengo et al 111AFPD433W,A2–3••••
Pengo et al 112AFRCT267W2–3/
1.5–2.0		•••
Perez-de-Llano113PERCT50A2–3•
Perez-Gomez114AFRCT479A2–3•••••
Perez-Gomez115AFRCT91–2–3•••••
Perez-Gomez116AFRCT496–2–3•••
PERSIST Investigators117DVTRCT132W2–3••
Petersen et al 118AFRCT67W2–3•
Poli et al 119VTEPD182W2–3••
Poli et al 120AFPD290–2–3•
Poli et al 121AFPD783W2–3••
Poli et al 122AFPD780W2–3••
Poli et al 123AFPD578–2–3••
Poller et al 124AF/VTERCT9148W, A, P2–3•
Prandoni (Galilei) et al 125VTERCT720W2–3•
Prandoni et al 126DVTRCT180–2–3•
Ridker et al 127VTERCT255W1.5–2••
Rombouts et al 128AFRCT104P2–3.5•
Sadanaga et al 129AFPD269W1.5–3••
Samsa et al 130AFRD660W2–3••••
Sarawate et al 131AFPD470W2–3•
Schulman et al 4VTERCT1265W2–3••
Schulman et al 5VTERCT1426W2–3•
Sconce et al 132AFRCT70W2–3•••
Shalev et al 133AFRD4408W2–3••••
Shen et al 134AFRD18 867W2–3••
Shen et al 135AFRD8992W2–3••
Sullivan et al 136AFRCT4060W2–3•
Suzuki et al 137AFPD667W1.6–2.6•
Tincani et al 138AFPD90W,A2–3••
van Bladel et al 139PEPD86A2–3.5•
van Dongen et al 140DVTPD244–2–3••
van Geest-Daalderop et al 141AFRD284A2–3.5•
van Gogh Investigators141aVTERCT2572W,A2–3••
Van Spall et al 143AFRCT6022W2–3••
Veeger et al 144VTERD2304A2–3.5•••••
Vene et al 145AFPD113W2–3•
Voller et al 146AFRCT202–2–3••••
Walker et al 147AFRD84W2–3••
Weimar et al 148AFPD252W2–3••
Weitz et al 149AFRCT250W2–3••
White et al 150AFRCT3587W2–3••••
Wieloch et al 151AF/VTERD15 264W2–3•••
Willey et al 152VTERD225W2–3•••
Wyse et al 153AFRCT4060W2–3•
Yamaguchi154AFRCT115W2.2–3.5/ 1.5–2.1•
Yamashita et al 155AFRCT129W2–3/
1.6–2.6		•
Yasaka et al 156AFPD88W–•
Yousef et al 157AFRD739W2–3••••

  • *‘Other’ includes: number of dosage changes; INR measure after a previously subtherapeutic or supratherapeutic INR; proportion of patients with ≥1INR measure below range after reaching an adequate INR; number of days until the next INR measure after an extreme measure; proportion of days with treatment stability (two consecutive INR measures in range); days to reach a therapeutic INR; mean time until stable (6 months within target INR range); minimum and maximum INR values per patient.

  • – Indicates data not reported.

  • A, acenocoumarol; AF, atrial fibrillation; DVT, deep vein thrombosis; F, fluindione; INR, international normalised ratio; N, sample size; PD, prospective design; P, phenprocoumon; PINRR, proportion of INR measures in range; PPIR, proportion of patients in range; RCT, randomised controlled trial; RD, retrospective design; T, tecarfarin; TTR, time in therapeutic range; VKA, vitamin K antagonist; VTE, venous thromboembolism; W, warfarin.